Delivery Order SPE2DB22D1106-SPE2DB25FETZ5
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,342.46 for Boostrix TDAP vaccine in 0.5mL syringe format on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting...
- The Defense Logistics Agency awarded a $3,991.50 delivery order to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine syringes (0.5mL) on August 25, 2025, with ultimate completion scheduled for August 26, 2025. This firm fixed price, competitively awarded contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract specifies performance...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine syringes (0.5mL) with a contract ceiling value of $7,909.80. This competitively awarded, firm fixed-price delivery order carries an ultimate completion date of July 30, 2025, and represents a child contract under AmerisourceBergen's larger federal contract portfolio. The product will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Boostrix TDAP vaccine in 0.5mL syringes, valued at $7,077.10 with a firm fixed price structure. This is a non-set-aside, competitively awarded contract with an ultimate completion date of August 20, 2025, and represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion global...
- The Defense Logistics Agency awarded a $2,594.20 delivery order to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine in 0.5ML syringes. This non-competitive delivery order, issued on August 8, 2025, with an ultimate completion date of August 11, 2025, represents a small-value transaction under a firm fixed-price arrangement. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen...
- The Defense Logistics Agency awarded a $1,064.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine syringes (0.5ML) on August 11, 2025, with completion targeted for August 12, 2025. This non-set-aside delivery order represents a small-value transaction under AmerisourceBergen's broader pharmaceutical supply arrangement with DLA. The product will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine syringes (0.5ML) valued at $1,044.92 under a firm fixed price contract with an ultimate completion date of August 28, 2025. This non-set-aside award represents a single delivery order positioned as a child contract, leveraging the company's extensive pharmaceutical supply capabilities and established federal procurement relationships. The vaccine delivery will be performed at...
- The Defense Logistics Agency awarded a $13,446.66 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Boostrix TDAP vaccine in 0.5mL syringes. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this competitive award. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 0.5ML Boostrix TDAP vaccine syringes with a contract value of $1,330.50 on August 14, 2025, with completion scheduled for August 15, 2025. This firm fixed price, non-set-aside delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The vaccine will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,435.48 to AmerisourceBergen Drug Corp for the supply of Boostrix TDAP vaccine in syringe format (0.5mL). This non-set-aside contract, awarded on August 27, 2025, with an ultimate completion date of August 28, 2025, represents a firm fixed-price delivery order. The place of performance is listed as Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters and a key distribution hub for the...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FETZ5Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,845.62 to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine syringes (0.5mL) on June 18, 2025, with an ultimate completion date of June 20, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value transaction within the company's broader pharmaceutical supply relationship with DLA. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a diverse range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, vaccines, and medical devices. The arrangement allows the company to serve the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through flexible procurement mechanisms aligned with DLA's strategic approach to establishing multiple regional pharmaceutical prime vendor contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 6/18/25 |